オプションチェーンは、TC BioPharm (Holdings)の株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、TC BioPharm (Holdings)の市場センチメントを評価します。.

TC BioPharm (Holdings) (NASDAQ:TCBP) 株価情報, オプションチェーン

TC BioPharm (Holdings)

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings) PLC

News

BHVN

Biohaven Announces FDA Acceptance And Priority Review Of Its New Drug Application For Troriluzole In Treatment Of Spinocerebellar Ataxia

Needham analyst Scott Berg maintains SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) with a Buy and lowers the price target from $230 to $210.

Price Target

Analyst Ratings

SPSC

Needham Maintains Buy on SPS Commerce, Lowers Price Target to $210

Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $19.584 million which missed the analyst consensus estimate of $27.266 million by 28.17 percent. This is a 24.59 percent decrease over sales of $25.971 million the same period last year.

Earnings

Earnings Misses

OESX

Orion Energy Sys Q3 2025 GAAP EPS $(0.05) Misses $(0.04) Estimate, Sales $19.584M Miss $27.266M Estimate

Needham analyst Charles Shi reiterates Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Buy and maintains $34 price target.

Reiteration

AMKR

Needham Reiterates Buy on Amkor Tech, Maintains $34 Price Target

Citigroup analyst Tyler Radke maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Neutral and raises the price target from $39 to $48.

KVYO

Citigroup Maintains Neutral on Klaviyo, Raises Price Target to $48

Citigroup analyst Drew Foster maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and raises the price target from $750 to $900.

HUBS

Citigroup Maintains Buy on HubSpot, Raises Price Target to $900

The OASIS+ vehicle has an estimated total spend of $60 billion over a maximum of 10 years.

Contracts

ASGN

ASGN Says Its Brand ECS Named As Prime Contractor On $60B OASIS+ IDIQ Contract

THRD

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

LASE

Laser Photonics Secures Repeat Order From Bruce Power, Advancing Eco-Friendly Laser Cleaning In Nuclear Plants

Morgan Stanley analyst Dara Mohsenian maintains Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) with a Underweight and lowers the price target from $35 to $32.

Morgan Stanley Maintains Underweight on Edgewell Personal Care, Lowers Price Target to $32

Laser Photonics Receives Order For Second And Third CleanTech 500-CTHD Laser Cleaning System From Sargent & Lundy For Use By Bruce Power In Ontario, Canada

Biotech

Guidance

Health Care

General

RPRX

Royalty Pharma Expects 2025 Portfolio Receipts Of $2.9B-$3.05B, With Operating And Professional Costs Of Approximately 10% Of Portfolio Receipts And Interest Paid Of $260M

Citigroup analyst Ronald Josey maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and raises the price target from $200 to $217.

EXPE

Citigroup Maintains Neutral on Expedia Group, Raises Price Target to $217

SPGI

S&P Global Authorized Repurchase Of Shares Totaling Up To $4.3B; Expects To Launch An Initial $650M Accelerated Share Repurchase In Coming Weeks

SHOP: -11% &#x7C; <a href="https://www.benzinga.com//node/43619343">Shopify shares are trading lower following Q4 financial results.</a>
&nbsp;
IINN: 33% &#x7C; <a href="https://www.benzinga.com//node/43618385">EXCLUSIVE: Inspira Technologies Tells Benzinga 'Initial ex-vivo testing demonstrates significant bacterial reduction potential for innovative IV dressing technology aimed at preventing bloodstream infections'</a>
&nbsp;
LIPO: 81% &#x7C; <a href="https://www.benzinga.com//node/43617270">Lipella Pharmaceuticals Shares Phase 2a Results For LP-310 In The Treatment Of Oral Lichen Planus, Showing Favorable Safety Profile And Tolerability Of Twice-Daily Oral Rinse</a>

Movers

Trading Ideas

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

LIPO

SHOP

Market-Moving News for February 11th

Needham analyst Quinn Bolton reiterates Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and maintains $70 price target.

LSCC

Needham Reiterates Buy on Lattice Semiconductor, Maintains $70 Price Target

Morgan Stanley analyst Toni Kaplan maintains Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) with a Underweight and lowers the price target from $102 to $100.

BFAM

Morgan Stanley Maintains Underweight on Bright Horizons Family, Lowers Price Target to $100

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.05 by 10.48 percent. This is a 0.87 percent increase over earnings of $1.15 per share from the same period last year. The company reported quarterly sales of $594.00 million which missed the analyst consensus estimate of $678.89 million by 12.50 percent. This is a 0.34 percent decrease over sales of $596.00 million the same period last year.

Royalty Pharma Q4 2024 Adj EPS $1.16 Beats $1.05 Estimate, Sales $594.00M Miss $678.89M Estimate

S&P Global Sees FY25 Revenue Growth Of 5%-7%, And Adjusted Diluted EPS Of $17.00-$17.25 Vs. $16.92 Estimate

FLXS

GigaCloud Technology Says Purple Innovation, Flexsteel Industries' Brand And Other Furniture Suppliers Has Joined Its GigaCloud Marketplace

TC BioPharm (TCBP) announced that shareholders have formally approved the recently announced 25% stock dividend. TC BioPharm declared that last wee...

TC Biopharm shareholders approve 25% stock dividend

The latest update is out from TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ). TC BioPharm conducted a general meeting on December 30, 2024, w...

TC BioPharm Approves Key Resolutions to Enhance Strategic Flexibility

TC BioPharm (TCBP) has advanced negotiations with both of its previously aforementioned acquisition candidates. This past spring TCBP announced the...

TC Biopharm advances negotiations with acquisition candidates

The latest update is out from TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ). TC Biopharm has announced the approval and distribution of a sp...

TC Biopharm Announces Special Stock Dividend and Temporary Trading Halt

These are the upcoming stock splits for the week of January 6 to January 10, based on&nbsp;TipRanks' Stock Splits Calendar. A&nbsp;stock split&nbsp...

Upcoming Stock Splits This Week (January 6 to January 10) – Stay Invested

TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ) has provided an announcement. TC Biopharm (Holdings) Plc announced that it received a notifica...

TC Biopharm Faces Potential Nasdaq Delisting Due to Bid Price Non-Compliance

TC BioPharm to implement ADS ratio change

19:50 EST TC Biopharm (TCBP) (Holdings) PLC – ADR trading halted, news pending Published first on TheFly – the ultimate source for real-time, marke...

TC Biopharm (Holdings) PLC – ADR trading halted, news pending

TC BioPharm (TCBP) announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, has...

TC Biopharm completes initial Cohort B patient dosing in ACHIEVE trial

TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ) has shared an update. On February 5, 2025, TC BioPharm announced a change in its American Depo...

Comments

TC BioPharm (Holdings)

TC BioPharm (Holdings) (TCBP) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル